Tecentriq
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Tecentriq in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Tecentriq.
36
Global Revenue Ranking
48
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Tecentriq
This is the first and only approved combination therapy for extensive-stage small cell lung cancer
Approximately 30,000 new cases of small cell lung cancer are reported in the US every year
Approximately 30,000 new cases of small cell lung cancer are reported in the US every year
Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes
Around 299,000 new cases of prostate cancer will be diagnosed in the US in 2024
The formulation reduces treatment time by around 80% compared to intravenous infusion
The deal includes a T-cell engager for lung cancer and neuroendocrine tumours
About 290,000 people in the US will be diagnosed with breast cancer in 2023
The formulation can cut treatment time by approximately 80% compared to intravenous infusion
Subcutaneous administration of Roche’s Tecentriq could cut treatment time by up to 75%
More than 900,000 people are diagnosed with the disease globally each year
Tecentriq in combination with Avastin significantly improved recurrence-free survival
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology